RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for...

RLAY stock soars on positive interim efficacy data from the early-stage study of its doublet therapy, RLY-2608 in combination with Faslodex, for...

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy...

Immunovant stock rises on mid-stage study data of batoclimab for Graves' Disease, showing superior efficacy compared to anti-thyroid drug therapy...

Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.

Terns Pharmaceuticals and Summit Therapeutics are in the spotlight following positive updates on key candidates.

Immuneering stock soars 41% as lead drug combo regimen shows superior initial efficacy in the first-line treatment of pancreatic cancer in a mid-stage...

NCNA stock surges 151% on positive efficacy data from the mid-stage melanoma study of NUC-7738 in combination with Merck's Keytruda.

ASND stock surges after data from a study shows that its investigational achondroplasia therapy achieved the primary study goal.

RHHBY's data on experimental obesity drug, CT-996, disappoints investors on higher incidence of adverse events.